Rosalind's 16th Delcath 13D Amendment Restates 2020 Board Seats, With Holding Capped By Blockers
The filing reports 6,692,491 shares, or 9.9% of the class, and restates how two Rosalind principals joined Delcath's board.
Rosalind Advisors and its affiliated funds filed Amendment No. 16 to their Delcath ownership filing on Monday, reporting 6,692,491 shares, or 9.9% of the class. The only text changed is Item 4, which restates how the firm's two principals joined Delcath's board in 2020.
What the amendment says
Item 4 recounts that on May 6, 2020, under a Board Appointment Agreement, Delcath's board expanded to eight members. It then elected Steven Salamon and Gilad Aharon as independent directors to fill the new seats.
Salamon, president and portfolio manager of Rosalind Advisors, was elected a Class III director, with a term scheduled to expire at the 2024 annual meeting. Aharon, the firm's secretary and portfolio manager, was elected a Class I director, with a term scheduled to expire at the 2025 annual meeting.
The event date on the filing is October 13, 2026. Items 3 and 6, covering funds and contracts, read "NA".
Why the stake is capped
The 9.9% is based on 34,698,795 common shares outstanding as of July 31, 2026, taken from Delcath's 10-Q. It gives effect to two conversion limits, called blockers.
The preferred stock cannot be converted if the holders would then own more than 9.99% of the common stock. The warrants cannot be exercised if that would take them above 4.99%.
Because of those limits, the filing says the reporting persons could not convert all of the reported preferred stock or exercise any of the reported warrants as of the event date. Actual common stock owned is therefore below the securities listed on the cover page.
Who holds what
Rosalind Opportunities Fund I reported 3,502,713 shares, or 4.9% of the class. Rosalind Master Fund reported 2,871,335 shares, or 4.5%.
Rosalind Advisors advises both funds and may be deemed the beneficial owner of their shares. The filing says Salamon may be deemed to own the preferred stock and warrant shares held by the Master Fund. The advisor and Salamon disclaim beneficial ownership of those shares.
In market data, Delcath closed at $14.37 on Monday, up about 2% from $14.08 in the prior session, for a market value of $489 million.
The amendment adds no new plans or demands. It restates the 2020 appointments and the 4.99% warrant cap that limits what Rosalind can convert into common stock.